Anthony Hunt - Sep 3, 2024 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Kenneth O'Brien (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Sep 3, 2024
Transactions value $
$0
Form type
4
Date filed
9/4/2024, 07:25 PM
Previous filing
Jun 14, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Disposed to Issuer $0 -13.1K -7.96% $0.00 152K Sep 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Disposed to Issuer $0 -13.1K -66.67% $0.00 6.53K Sep 3, 2024 Common Stock 13.1K $192.71 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 28, 2024 (the "Effective Date"), the Issuer and Mr. Hunt entered into an amendment (the "2024 Equity Award Amendment") to certain of Mr. Hunt's equity awards, pursuant to which, effective as of September 1, 2024, Mr. Hunt forfeited two thirds of the number of shares of the Issuer's Common Stock underlying the time-based restricted stock unit award, performance-based restricted stock unit awards and stock option granted to Mr. Hunt on February 27, 2024 that remain outstanding as of the Effective Date.
F2 Pursuant to the 2024 Equity Award Amendment, one third of the remaining stock options will vest and become exercisable on February 27, 2025, February 27, 2026, and February 27, 2027.